This project will take robust evidence regarding inflammation based management, comorbidity and self management and translate it into practice using a national implementation framework.
Localised Airway Reactivity As A Determinant Of Asthma Control And AHR
Funder
National Health and Medical Research Council
Funding Amount
$306,562.00
Summary
Asthma morbidity and mortality remain high, with drug cost, days lost from school and work. This may be due to severe asthma in which control cannot be attained. This may be due to localised regions of lung that remain persistently responsive to inhaled irritants. We will examine the location and size of these regions using 3-dimensional ventilation scanning. The potential importance of our findings is in providing a basis for improving treatment in resistant, severe asthma.
Centre Of Research Excellence In Asthma Treatable Traits (CREATT)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
This CRE will focus on personalised medicine in asthma, specifically using the treatable traits approach. We have identified disease management areas of highest importance to people with asthma and health care providers. We will generate new knowledge, develop and strengthen collaborations and train translation focused researchers to develop high quality evidence and translate this to practice.
National Clinical Centre Of Research Excellence In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$2,597,952.00
Summary
Severe Asthma remains a large burden for the Australian community. It does not respond to current management approaches. We will develop and implement a targetted therapy approach to severe asthma that will involve assessment of needs of people with severe asthma, community burden form severe asthma, biomarkers and linked treatment strategies, as well as knowledge transfer tools and training of the health and medical workforce.
Elucidating The Roles And Mechanisms Of Activation Of NLRP3 Inflammasomes And Developing Therapeutic Interventions For Severe Steroid-resistant Asthma
Funder
National Health and Medical Research Council
Funding Amount
$961,929.00
Summary
Severe asthma is a major clinical issue. There are no effective treatments because we don’t understand how it occurs. We have identified a factor called an “inflammasome” that we think causes severe asthma. We have produced a new inhibitor of this factor, and shown experimentally that it may suppress important symptoms of severe asthma. We now aim to work out precisely how this inflammasome causes severe asthma and progress our new inhibitor towards therapeutic development.
Targeting Neutrophil Extracellular Traps To Reduce Inflammation In Severe Asthma
Funder
National Health and Medical Research Council
Funding Amount
$585,240.00
Summary
People with severe asthma, a chronic disease of the lungs, often have many inflammatory cells in the airways called neutrophils. Neutrophils release a meshwork of fibers in a web like trap called NETs, which are made of the cells DNA and other proteins that fight infection. These NETs can promote inflammation in the persons airways. Current asthma treatments have no effect on NETs. This project will measure NETs in the airways and test a new treatment to reduce NETs, and relieve asthma symptoms.
Elucidating The Mechanisms Of Infection-induced, Steroid-resistant Asthma
Funder
National Health and Medical Research Council
Funding Amount
$348,070.00
Summary
Steroid-resistant asthma is an important clinical problem and effective therapies are urgently required. Substantial evidence links bacterial and viral respiratory infections with steroid-resistant asthma, however, how infections are associated with steroid-resistant asthma is not known. This project will investigate the role of specific immune factors, that we have identified, in infection-induced steroid-resistant asthma. Our project may identify new therapeutic targets for this severe form of ....Steroid-resistant asthma is an important clinical problem and effective therapies are urgently required. Substantial evidence links bacterial and viral respiratory infections with steroid-resistant asthma, however, how infections are associated with steroid-resistant asthma is not known. This project will investigate the role of specific immune factors, that we have identified, in infection-induced steroid-resistant asthma. Our project may identify new therapeutic targets for this severe form of asthma.Read moreRead less
Outcome Of Childhood Asthma In Adult Life And The Interaction With COPD
Funder
National Health and Medical Research Council
Funding Amount
$503,549.00
Summary
The Melbourne Study of Childhood Asthma (MESCA) is the longest, most comprehensive follow-up study of childhood asthma. The members were recruited in 1964 at the age of 7 and they have been reviewed at ages 10, 14, 21, 28, 35 and 42 years of age with a retention rate of 87% of survivors at the most recent follow-up. To date, the MESCA study has provided comprehensive data on the outcome of childhood asthma through to their adult years and has been particularly influential in establishing approac ....The Melbourne Study of Childhood Asthma (MESCA) is the longest, most comprehensive follow-up study of childhood asthma. The members were recruited in 1964 at the age of 7 and they have been reviewed at ages 10, 14, 21, 28, 35 and 42 years of age with a retention rate of 87% of survivors at the most recent follow-up. To date, the MESCA study has provided comprehensive data on the outcome of childhood asthma through to their adult years and has been particularly influential in establishing approaches to treatment of paediatric asthma nationally and internationally. The results of the study have been published widely over the years and cited extensively. The members of this cohort turn 50 in 2007 and will be invited to participate in a further review to reassess their clinical outcome to examine the relationship between long standing asthma and the development of COPD. Those members of the cohort who have had asthma persisting through their adult years have a degree of fixed obstruction on their tests of lung function and are potentially at risk of developing COPD. Some are at increased risk as approximately 30% of the members are regular smokers. In this review, at age 59 years, there is an excellent opportunity to examine the interaction of asthma and COPD and to compare the inflammatory processes between those who have continuing asthma, those whose asthma has resolved and in each group examine the effect of smoking. We will also look at a numbers of genetic markers associated with COPD to identify those who are more susceptible to the development of COPD. A second area of interest is the components of the immune system that influence asthma.. In an earlier study we identified one component of the immune system, known as the T cell system, that had returned to normal in those whose asthma had resolved. In this review, we plan to examine the T cell system in detail to understand what mechanisms may be responsible for resolution of childhood asthma.Read moreRead less
Airway Inflammometry For Asthma And COPD: Practitioner Fellowship Peter G Gibson
Funder
National Health and Medical Research Council
Funding Amount
$568,892.00
Summary
Asthma and chronic obstructive pulmonary disease will receive the benefits of personalized medicine with this Fellowship funding. Dr Gibson, an international leader in this field, has identified key biomarkers that will allow treatments to be rationalized based on the underlying disease mechanisms. This research will translate the benefits on modern technology and apply these to individualized care for people with asthma and COPD, who can expect fewer lung attacks and better quality of life.
Role Of Toll-like Receptor 7 In Rhinovirus-induced Asthma Exacerbation
Funder
National Health and Medical Research Council
Funding Amount
$697,248.00
Summary
One third of the annual asthma-related health care expenditure may be attributable to asthma-related hospitalisations. Even mild asthmatics experience severe exacerbations at a rate of almost one per year1 and those attacks can be fatal. Rhinovirus (RV) causes the majority of asthma exacerbations which may be linked to an impaired antiviral interferon (IFN) response in asthmatics. RV is sensed by Toll-like receptor (TLR) 7, but the role of this innate host defence pathway in regulating antiviral